This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Accelrys Announces Software Licensing Agreement With Gulf Coast Consortia

SAN DIEGO, May 30, 2012 /PRNewswire/ -- Accelrys, Inc. (NASDAQ: ACCL), a leading enterprise R&D software and services company, today announced that the Gulf Coast Consortia (GCC) for Quantitative Biomedical Sciences has signed a five-year licensing agreement with Accelrys to provide investigators in the GCC Chemical Genomics (GCC-CG) program with access to scientific software, services and training. The Accelrys software will be used to support multi-disciplinary collaborative research and training programs for the treatment and prevention of diseases, including rare and undertreated cancers.

To view the multimedia assets associated with this release, please click http://www.prnewswire.com/news-releases/accelrys-announces-software-licensing-agreement-with-gulf-coast-consortia-155506635.html

Offered through the Accelrys Academic Program, the licensed software includes the scientifically enabled, enterprise-scalable Accelrys Enterprise Platform supporting multi-center, collaborative information sharing and scientific innovation across partnering research organizations. The system also includes Accelrys Pipeline Pilotâ„¢ (the platform's scientific authoring solution), the Cloud-based Accelrys HEOS®  drug discovery information management workspace, the Accelrys Discovery Studio® modeling and simulation application and Accelrys Biological Registration software.

"Plug-and-play deployment and ease of use in a seamless integrated network requiring minimal support by internal resources were the driving factors that led our group to adopt Accelrys technology," said GCC-CG director and co-founder Dr. Peter Davies, professor and director of the Center for Translational Cancer Research, Institute of Biosciences and Technology, Texas A&M Health Center. "With upwards of thirty projects a year, we need to work together efficiently and generate results quickly with minimal time and resources spent on internal software development. The ability to create Pipeline Pilot Web applications that can be freely shared with other academic researchers inside or outside the Consortia provides a significant collaboration and innovation benefit."

Dr. Michael Mancini, associate professor in the department of Molecular and Cellular Biology at Baylor College of Medicine, and co-founder/co-director of the GCC-CG added "For several years, our assay development efforts and screening program have always had a sizable high throughput microscopy-based emphasis using Pipeline Pilot-based imaging tools. We are extremely pleased to now be able to integrate high content analysis/screening data and reporting across the entire program using HEOS."

The mission of the GCC is to build and support interdisciplinary collaborative research teams and training programs in the biological sciences and apply the resulting expertise and knowledge to the treatment and prevention of diseases. The GCC brings together preeminent principal investigators from several world-renowned research institutions including the founding members:

  • Baylor College of Medicine
  • Rice University
  • University of Houston
  • University of Texas Health Science Center at Houston (UTHealth)
  • University of Texas MD Anderson Cancer Center
  • University of Texas Medical Branch at Galveston

In addition to the GCC founding institutions, the GCC-CG includes The Methodist Hospital Research Institute, The University of Texas at Austin - Texas Institute for Drug and Diagnostic Development, Texas A&M Health Science Center – Institute for Biosciences and Technology, Texas Southern University and The University of Texas-El Paso.

"Large inter-institutional cooperatives focused on collaborative research and interdisciplinary training represent a new operating paradigm in academia today," said Accelrys Senior Vice President and Chief Technology Officer, Dr. Matt Hahn. "Accelrys' unifying Enterprise Platform defines a new standard in integrated research informatics for multi-center collaborations. The software package tailored for GCC and delivered through Accelrys' Academic Program provides immediate access to shared state-of-the-art solutions, enabling university partners to hit the ground running with project delivery."

Visit the Accelrys Academic microsite to learn more about how the Accelrys Academic Program is advancing academic research.

About Accelrys, Inc.

Accelrys (NASDAQ: ACCL), a leading scientific enterprise R&D software and services company, supports industries and organizations that rely on scientific innovation to differentiate themselves. The industry-leading Accelrys Enterprise Platform provides a broad, flexible scientific solution optimized to integrate the diversity of science, experimental processes and information requirements across the research, development, process scale-up and early manufacturing phases of product development. By incorporating capabilities in applications for modeling and simulation, enterprise lab management, workflow and automation, and data management and informatics, Accelrys enables scientific innovators to access, organize, analyze and share data in unprecedented ways, ultimately enhancing innovation, improving productivity and compliance, reducing costs and speeding time from lab to market.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,279.74 +13.75 0.08%
S&P 500 2,010.40 -0.96 -0.05%
NASDAQ 4,579.7890 -13.6380 -0.30%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs